Need Help?
Copied to clipboard!

Patient-Derived Xenografts in Multiple Myeloma

Samples from patients with multiple myeloma or related plasma cell dyscrasias were CD138+ selected and injected into SCID-Rab mouse model to generate patient-derived xenografts (PDX). Resulting PDX models underwent genomic and transcriptomic sequencing and were compared to the original patient sample to determine the effect of passage in a mouse on evolution of the disease and selection of subclones. High risk markers, such as gain 1q, abnormal TP53 or CDKN2C, as well as common drivers including NRAS and KRAS were characterized for risk and subclone analysis. In addition, immunotherapy targets such as TNFRSF17 were analyzed for treatment relapse analysis.

Some patient data overlaps with previous submissions including phs003772, phs003220, or phs003908 and sequencing data are available in SRA.